{"id":23099,"date":"2023-08-02T10:00:24","date_gmt":"2023-08-02T08:00:24","guid":{"rendered":"https:\/\/idibell.cat\/es\/?p=23099"},"modified":"2023-07-28T12:45:45","modified_gmt":"2023-07-28T10:45:45","slug":"un-nuevo-farmaco-neuroprotector-muestra-buenos-resultados-preliminares-para-el-ictus-isquemico","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2023\/08\/un-nuevo-farmaco-neuroprotector-muestra-buenos-resultados-preliminares-para-el-ictus-isquemico\/","title":{"rendered":"Un nuevo f\u00e1rmaco neuroprotector muestra buenos resultados preliminares para el ictus isqu\u00e9mico"},"content":{"rendered":"<p>La prestigiosa revista cient\u00edfica <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37338893\/#:~:text=Conclusions%20and%20relevance%3A%20In%20acute,90%20days%20compared%20with%20placebo.\">JAMA Neurology<\/a> ha publicado resultados positivos de un ensayo cl\u00ednico denominado APRIL, que ha evaluado el efecto de un innovador f\u00e1rmaco neuroprotector llamado ApTOLL en combinaci\u00f3n con un tratamiento endovascular en pacientes con ictus isqu\u00e9mico agudo.<\/p>\n<p>El estudio ha demostrado que la administraci\u00f3n de ApTOLL dentro de las 6 horas posteriores al ictus, junto con el tratamiento endovascular, es segura y bien tolerada. Adem\u00e1s, los pacientes que recibieron ApTOLL mostraron una significativa reducci\u00f3n de la mortalidad (del 18% al 5%) y una mejora en la funcionalidad a los 90 d\u00edas en comparaci\u00f3n con los pacientes que recibieron un placebo.<\/p>\n<p>El Dr. Pere Cardona, director de la Unidad de Ictus del Hospital Universitario de Bellvitge (HUB) e investigador principal del grupo de <a href=\"https:\/\/idibell.cat\/es\/investigacion\/area-de-neurociencias\/programa-de-neurociencias\/enfermedades-neurologicas-y-neurogenetica\/\">Enfermedades Neurol\u00f3gicas y Neurogen\u00e9tica<\/a> del IDIBELL, ha destacado la importancia de estos resultados: \u201cApTOLL es el primer f\u00e1rmaco neuroprotector que ha mostrado gran eficacia y seguridad en la fase aguda del ictus grave. Esto hace que sea un candidato prometedor para futuros estudios en entornos hospitalarios y prehospitalarios\u201d.<\/p>\n<p>El estudio APRIL se ha realizado en 14 centros de referencia en ictus en Espa\u00f1a y Francia e incluy\u00f3 a 151 pacientes que fueron aleatorizados por recibir ApTOLL o un placebo antes de la trombectom\u00eda, siendo el criterio principal de valoraci\u00f3n la seguridad determinada por la muerte, la hemorragia intracraneal sintom\u00e1tica, los accidentes cerebrovascular maligno y recurrente. Tambi\u00e9n se evaluaron el volumen del infarto y la gravedad de los s\u00edntomas a las 72 horas y la discapacidad a los 90 d\u00edas.<\/p>\n<p>El ictus es una enfermedad grave que afectar\u00e1 a 1 de cada 4 adultos mayores de 25 a\u00f1os a lo largo de su vida, siendo el ictus isqu\u00e9mico agudo es la forma m\u00e1s com\u00fan. A pesar de los tratamientos de reperfusi\u00f3n, muchos pacientes siguen desarrollando importantes discapacidades. Por eso, ApTOLL surge como una esperanza prometedora como f\u00e1rmaco neuroprotector para mejorar los resultados del ictus en combinaci\u00f3n con otros tratamientos. Adem\u00e1s, es importante destacar que ApTOLL ya cuenta con la designaci\u00f3n de medicamento prioritario de la Agencia Europea de Medicamentos (EMA), reconociendo su importancia potencial en el campo m\u00e9dico.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seg\u00fan los resultados del estudio APRIL, en los que han participado el Hospital de Bellvitge y el IDIBELL, ApTOLL ha mostrado una buena seguridad en 151 pacientes de ictus isqu\u00e9mico agudo.<\/p>\n","protected":false},"author":8,"featured_media":23101,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[320,300,277],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-23 23:42:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23099"}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=23099"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23099\/revisions"}],"predecessor-version":[{"id":23104,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23099\/revisions\/23104"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/23101"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=23099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=23099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=23099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}